Metabolic Health
HbA1c, insulin sensitivity, lipid panels, and blood pressure beyond weight loss
Beyond the Scale
Weight loss is the headline, but retatrutide's metabolic effects go far deeper. The Phase 2 trial in people with Type 2 diabetes showed HbA1c reductions rivaling dedicated diabetes drugs, alongside improvements in triglycerides, blood pressure, and insulin sensitivity. This unit examines the cardiometabolic data that could make retatrutide relevant well beyond obesity treatment.
HbA1c Reduction
Glycemic control data from both the obesity and Type 2 diabetes trials.
Insulin Sensitivity
HOMA-IR improvements and the role of weight loss vs direct receptor effects.
Lipid Panel Changes
Triglyceride, LDL, HDL, and total cholesterol effects across dose tiers.
Blood Pressure
Systolic and diastolic blood pressure changes and cardiovascular implications.